Zagfen (ZFGN) shares were flying high on Wednesday following results from a Phase III drug trial.
Zagfen’s bestPWS ZAF-311 drug trial saw positive results from its obesity drug beloranib in reducing body weight and hyperphagia-related behaviors. It’s the only investigational drug to have achieved positive results in both of these areas.
The Phase III trial for Zagfen’s beloranib was a double blind study that was placebo controlled. It lasted for six months and tested the drug in patients that have Prader-Willi syndrome. There were 2.4 mg and 1.8 mg doses of the drug being tested.
The 2.4 mg and 1.8 mg doses of beloranib resulted in a roughly 9% and 8% decrease in body weight. They also both were successful at decreasing hyperphagia-related behaviors by 7 units and 6.3 units when compared to a placebo.
ZFGN shares were up 58% as of Noon Tuesday.
More From InvestorPlace:
